A Global, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
This research is a global study looking into a new treatment, mRNA-3705, for people with a rare inherited condition called isolated methylmalonic acidemia (MMA). This condition means the body can't properly break down certain proteins, leading to a build-up of harmful substances. The study is divided into different parts. In some parts, doctors are focusing on how safe the new mRNA-3705 medicine is and how well people tolerate it. In other parts, they are also checking to see how the medicine moves through the body and if it helps to lower the levels of methylmalonic acid in the blood, which is a key marker for this condition. They will compare mRNA-3705 to a dummy medicine (placebo) to see its effects.
Överblick
Vad handlar denna studie om?
This study is investigating a new medicine called mRNA-3705 for a rare, inherited condition known as isolated methylmalonic acidemia (MMA). People with MMA have trouble breaking down certain protein building blocks in their body. This happens because they don't have enough of a specific enzyme (a natural protein that speeds up chemical reactions) called methylmalonyl-CoA mutase, or it doesn't work properly. When this enzyme is missing or faulty, harmful substances, like methylmalonic acid, build up in the body, which can lead to serious health problems.
The main goals of this study are to find out if mRNA-3705 is safe for people to take, how well their bodies tolerate it, and how the body handles the medicine (like how it's absorbed, distributed, and removed). Importantly, the researchers also want to see if the medicine can help to reduce the levels of methylmalonic acid in the blood, which is a key indicator of effective treatment for MMA.
This is a 'Phase 1/2' study, which means it's one of the first times this medicine is being given to people. The study is split into several parts. Some parts will focus primarily on safety, while others will compare the new medicine to a saline injection (a dummy medicine or placebo) to measure its effectiveness in lowering acid levels and improving overall health, including how patients feel and their hospital experiences.
Viktiga punkter
- This study is testing a new medicine (mRNA-3705) for a rare genetic condition called isolated methylmalonic acidemia (MMA).
- Its main goals are to check if the medicine is safe, well-tolerated, and can reduce harmful acid levels in the blood.
- This is an early-stage study, meaning it's one of the first times the medicine is used in people.
- Deltagarna kommer att få antingen den nya medicinen eller en placebo (overksam medicin).
- You must be at least 18 years old to participate, and a medical assessment will determine if you are suitable.
Vem kan vara berättigad?
To be able to take part in this study, you must be at least 18 years old. Both men and women can join the study.
There will be other, more detailed health requirements that the doctors will discuss with you. These are put in place to make sure the study is safe for everyone involved and that the results of the research are clear and accurate. For example, doctors might need to check your general health, your specific MMA condition, and any other medicines you are taking.
If you are interested in joining, the study team will go through all the requirements with you to see if this study is a good fit for your situation.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du 18 år eller äldre?
- Have you been diagnosed with isolated methylmalonic acidemia?
- Kan du delta i regelbundna klinikbesök?
- Are you willing to potentially receive either the new medicine or a placebo (dummy treatment)?
Vad innebär deltagande?
If you decide to participate in this study, you will receive either the new medicine, mRNA-3705, or a placebo (a salt-water injection that looks like the study medicine but has no active drug). You won't know which one you are receiving.
Your participation will involve regular visits to the clinic for check-ups. These visits will include various assessments, such as blood tests to measure the levels of certain substances in your body and to check how the medicine is affecting you. Doctors will also monitor you closely for any side effects. You might also be asked to fill out questionnaires about how you are feeling and your quality of life. The total duration of your participation will be explained to you by the study team, including how long you'll be taking the medicine and any follow-up appointments.
Potentiella risker och fördelar
Platser (3)
- —ObekräftadFrankrike
- —ObekräftadNederländerna
- —ObekräftadSpanien
Vanliga frågor
What is methylmalonic acidemia (MMA)?
MMA is a rare, inherited condition where your body can't properly break down certain foods, leading to a build-up of harmful acids.
What is mRNA-3705?
It's a new medicine being tested to help your body make the missing enzyme that causes MMA, to reduce harmful acid levels.
What does 'Phase 1/2 study' mean?
This means it's one of the first times this new medicine is being given to people. Doctors are mainly checking its safety and looking for early signs of how well it works.
Will I receive the new medicine or a dummy treatment?
In some parts of the study, you might receive the new medicine or a dummy treatment (placebo). Neither you nor your doctor will know which one you're getting.
Hur länge behöver jag vara med i studien?
The study team will explain the exact time commitment, including how long you'll take the medicine and any follow-up appointments, as it can vary.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Intresserad av att delta?
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.